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Abstract 
Mycobacterium tuberculosis arabinogalactan (AG) is an essential cell wall component. It 
provides a molecular framework serving to connect peptidoglycan to the outer mycolic 
acid layer. The biosynthesis of the arabinan domains of AG and lipoarabinomannan 
(LAM), occurs via a combination of membrane bound arabinofuranosyltransferases, all 
of which utilise decaprenol-1-monophosphorabinose as a substrate (DPA). The source of 
arabinose ultimately destined for deposition into cell wall AG or LAM, originates 
exclusively from phosphoribosyl-1-pyrophosphate (pRpp), a central metabolite which is 
also required for other essential metabolic processes, such as de novo purine and 
pyrimidne biosynthesis. In M. tuberculosis, a single pRpp synthetase enzyme (Mt-PrsA) 
is soley responsible for the generation of pRpp, by catalysing the transfer of 
pyrophosphate from ATP to the C1 hydroxyl position of ribose-5-phosphate. Here, we 
report a detailed biochemical and biophysical study of Mt-PrsA, which exhibits the most 
rapid enzyme kinetics reported for a pRpp synthetase.  
 
Key words: Mycobacteria/ cell wall/ polysaccharides/ arabinan/ 
phosphoribosylpyrophosphate 
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Introduction 
As we enter into the second decade of the twenty first century, tuberculosis (TB) 
continues to cause more deaths and human suffering than any other infectious disease 
(Dye, 2006). The number of new TB cases is increasing at an alarming pace, as does the 
prevalence of drug resistant stains of the causative agent, Myobacterium tuberculosis, in 
the form of multidrug-resistant TB (MDR-TB) and extensively drug resistant TB (XDR-
TB) (Madariaga et al., 2008). The need for new drugs and vaccines to combat this major 
burden to human health is overwhelming. 
 
The unique hydrophobic cell wall of M. tuberculosis forms a primary defensive barrier to 
the onslaught of toxic insult during the host immune response. The current 
chemotherapeutic regime used to treat TB includes the administration of isoniazid and 
ethambutol, both of which target crucial steps in the biosynthesis and assembly of the M. 
tuberculosis cell wall (Banerjee et al., 1994; Belanger et al., 1996). However, whilst 
these cell wall inhibitors are excellent at effectively killing actively dividing cells, certain 
sub-populations of bacilli, labelled as ‘persisters’, exhibit transient resistance to many of 
the drugs used to treat TB (Wayne & Sohaskey, 2001). The precise molecular mechanism 
of this latent infection caused by persistent bacilli is poorly understood. However, in the 
pursuit of identifying suitable cellular targets and the development of new anti-TB 
chemotherapeutic agents, we must address the phenomenon of persistence to truly 
eradicate the disease. Recently it has been shown that certain processes of metabolic 
pathways involved in mycobacterial cellular energy metabolism, such as respiratory ATP 
biosynthesis, represent excellent physiological targets for the effective killing of latent 
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populations of TB bacilli (Bald & Koul, 2010; Koul et al., 2007; Koul et al., 2008). 
Phospho-α-D-ribosyl-1-pyrophosphate (pRpp) is a central metabolite that links the 
pentose phosphate pathway to the de novo and salvage biosynthetic pathways of purine 
and pyrimidine production, NAD and NADP cofactor biosynthesis, as well as histidine 
and tryptophan biosynthesis (Hove-Jensen, 1988). It is therefore considered that pRpp is 
required at all times during the life cycle of both prokaryotic and eukaryotic cells (Hove-
Jensen, 1989; Tozzi et al., 2006). In addition to these central metabolic processes 
described above, members belonging to the Corynebacteriacae, such as mycobacteria, 
have evolved an almost unique biochemical pathway, utilising pRpp as a high-energy 
biosynthetic precursor for cell wall arabinan biosynthesis (Scherman et al., 1995; 
Scherman et al., 1996; Wojtkiewicz et al., 1988) (Fig. 1). The gene product of Rv3806c 
encodes for a membrane bound pRpp:decaprenol-1-monophosphate 5-
phosphoribosyltransferase (DPPR synthase) which catalyses the formation of decaprenol-
1-monophosphoribose-5-phosphate (DPPR) and pyrophosphate from pRpp and 
decaprenol-1-monophosphate (Huang et al., 2005). DPPR then undergoes C5-
dephosphorylation to decaprenol-1-monophosphoribose (DPR) and epimerisation about 
the C2-OH position of the ribosyl moiety catalysed by a two-step heteromeric 
oxidation/reduction process (Mikusova et al., 2005). In M. tuberculosis, Rv3790 encodes 
for a FAD-containing oxidoreductase (DprE1) which oxidises the ribosyl C2-OH group 
to the keto sugar decaprenol-1-monophosphoryl-2-keto-β-erythro-pentofuranose (DPX) 
which is subsequently reduced by DprE2 (encoded by Rv3791) forming decaprenol-1-
monophosphoarabinose (DPA) (Mikusova et al., 2005), which is the sole high-energy 
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lipid linked substrate for the GT-C family arabinofuranosyltransferases (AraTs) which 
are involved in cell wall arabinan polymerisation (Alderwick et al., 2007). 
 
Mycobacterial arabinan is a highly branched polysaccharide consisting of arabinose units 
arranged into specific repeating motifs, and it predominantly features in the 
heteropolysaccharide arabinogalactan (AG), which is a crucial component of the 
mycobacterial cell wall (Besra et al., 1995; Daffé et al., 1990). Three arabinan domains 
are covalently linked via an Araf-α(1→5)-Galf glycosidic bond to the 8th, 10th and 12th 
positions of a single linear polysaccharide composed of ~30 alternating β(1→5) and 
β(1→6) Galf residues forming the galactan domain of AG (Alderwick et al., 2005). AG is 
a structural macromolecule and serves to function as a molecular scaffold linking 
peptidoglycan (PG) to the mycolic acids, forming a highly impermeable and hydrophobic 
layer surrounding the mycobacterial cell (McNeil et al., 1991). Arabinan is also present 
in the form of lipoarabinomannan (LAM), a highly immunogenic lipoglycan, which is 
involved in modulating the host immune response (Briken et al., 2004). In terms of 
chemical composition, arabinan represents approximately 18% of mycobacterial cell wall 
biomass (Ortalo-Magne et al., 1995). Therefore, during cell elongation and division of 
the mycobacterial bacilli, it is necessary for there to be a readily available supply of pRpp 
for the efficient incorporation of arabinose into newly synthesised cell wall material. 
During this process, the metabolic demand for pRpp is likely to increase dramatically and 
the elevated levels required for effective arabinan biosynthesis must be maintained. The 
enzyme pRpp synthetase (ATP: α-D-ribose-5-phosphate pyrophosphotransferase; 
EC2.7.6.1) belongs to a family of enzymes that catalyse the transfer of the β,γ-
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diphosphate moiety from ATP to the C1-OH group of α-D-ribose-5-phosphate (R5P) and 
the gene(s) encoding for this enzyme(s) is present in all living organisms (Carter et al., 
1997; Hove-Jensen, 1985; Krath & Hove-Jensen, 1999). It is predicted that the M. 
tuberculosis H37Rv genome codes for only one pRpp synthetase (Rv1017c), which is 
annotated as Mt-PrsA (Cole & Barrell, 1998). 
 
In this study, we report a detailed biochemical characterisation of recombinant Mt-PrsA 
and provide evidence which confirms the essentiality of this gene for the maintenance of 
cell growth, division and integrity. Mt-PrsA displays an absolute requirement for 
inorganic phosphate for enzyme activation and will accept either Mg2+ or Mn2+ as 
divalent cations, which serve to coordinate the phosphate moieties of ATP during enzyme 
catalysis. Using a continuous enzyme coupled spectrophotometric assay, we report a 
detailed kinetic characterisation of Mt-PrsA, which displays the highest specific activity 
measured for any a pRpp synthetase studied to date. By investigating the oligomeric state 
of Mt-PrsA in solution and measuring the ligand binding properties of its substrates, we 
provide evidence suggesting that the mechanism by which ADP inhibits Mt-PrsA 
activity, results from the binding of ADP to an allosteric site, and as a consequence, 
induces the stabilisation of an inactive, hexameric oligimeric species.  
 
Results 
Evidence suggesting that Mt-prsA is an essential gene for the maintenance of cellular 
integrity 
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Mt-prsA is predicted to be an essential gene as determined by high density transposon 
mutagenesis (Sassetti et al., 2003). This is not unsurprising, considering the apparent 
physiological importance of Mt-PrsA in the provision of pRpp for central metabolic 
pathways and the formation of the cell wall biosynthetic precursor DPA (Scherman et al., 
1995; Wolucka et al., 1994). We have previously used Corynebacterium glutamicum as 
an excellent model system for the study of complex cell wall biosynthetic processes, and 
we have reported the phenotypic characterisation of several cell wall mutants, which 
would otherwise be essential in mycobacterial systems (Alderwick et al., 2005; 
Alderwick et al., 2006a; Alderwick et al., 2006b; Birch et al., 2008; Gande et al., 2004; 
Seidel et al., 2007). A bioinformatics analysis of several Corynebacteriaceae genomes 
revealed that NCgl0945 (Cg-prsA) was the likely C. glutamicum ortholog of Mt-prsA 
(Rv1017c). These corresponding gene products share 71% identity (83% similarity) and 
the gene locus is conserved within the Corynebacteriaceae indicating that this region is 
syntenic. We attempted to inactivate Cg-prsA in C. glutamicum, by using the disruption 
vector pK18mob-Cg-prsA-int, carrying 304 bp of Cg-prsA. In a control experiment, we 
used the previously reported pK18mob-Cg-ppm1-int construct, which affords the 
successful inactivation of the gene encoding for the polyprenyl monophosphomannose 
synthase (ppm1) of C. glutamicum, which is a gene of similar size to that of Cg-prsA 
(Gibson et al., 2003). Both inactivation vectors were used in parallel experiments for the 
transformation of wild type (WT) C. glutamicum to kanamycin resistance (KanR). Whilst 
we were able to easily generate C. glutamicum KanR colonies from the pK18mob-Cg-
ppm1-int construct, we were required to conduct several rounds of electroporation using 
pK18mob-Cg-prsA-int before obtaining three separate C. glutamicum KanR clones. This 
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indicates that the recombination events appeared to have taken place at unexpected and, 
as yet, undefined loci. From this analysis, we concluded that Cg-prsA is an essential gene 
and its function is necessary for the growth and integrity of C. glutamicum, even when 
grown on rich Brain Heart Infusion (BHI) medium.  
 
Over-expression, purification and pRpp synthetase activity of recombinant Mt-PrsA 
Over-expression of Mt-PrsA in Escherica coli C41 cells and the subsequent purification 
by IMAC, resulted in a preparation of Mt-PrsA that was stable in solution at a 
concentration of 2 mg/ml. A coomassie-stained 12 % SDS-PAGE analysis of Mt-PrsA 
revealed a band that migrated to a position of 35 kDa, which is in accordance with the 
expected molecular weight of Mt-PrsA and was estimated to be at least 98% pure. To 
determine if recombinant Mt-PrsA was active, we performed a radiochemical assay to 
measure the pyrophosphate transfer from ATP to the C1-OH group of [14C]-uniformly 
labelled R5P (Boss et al., 1984). Starting with [14C]-U-D-glucose, and replicating the first 
three enzymic reactions of the pentose phosphate pathway in vitro using commercially 
available enzymes (Roche and Sigma), we prepared a source of purified [14C]-U-α-D-
ribose-5-phosphate as a substrate for subsequent enzyme assays. In a time course assay, 
recombinant Mt-PrsA exhibited rapid pRpp synthetase activity which was dependent 
upon the presence of either of the divalent cations Mg2+ and Mn2+, with slight preference 
for the latter (Fig. 2a). During the assay, p[14C]Rpp is susceptible to product degradation 
due to hydrolysis of the labile C1-OH pyrophosphate bond, which accounts for the 
relatively small increase in band density (relating to p[14C]Rpp) over the course of the 
assay. Addition of EDTA to the reaction mix inhibited the formation of p[14C]Rpp (data 
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not shown) and the inclusion of CaCl2, in replacement of MgCl2 or MnCl2, also resulted 
in loss of Mt-PrsA activity (Fig 2a). Mt-PrsA was found to be most active at a pH of 6.5, 
but also showed activity across a broad range of pH levels (4.5 – 9.5) and was only found 
to be inactive at high pH (10.5) (data not shown). In accordance with previous studies of 
pRpp synthetases (Prs) from other organisms, Mt-PrsA was strongly inhibited by the 
presence of ADP, which has been shown to be an allosteric modulator of this class of 
enzymes (Fig. 2b) (Arnvig et al., 1990; Eriksen et al., 2000; Gibson et al., 1982; Switzer 
& Sogin, 1973; Willemoes et al., 2000). 
 
Mt-PrsA-dependent metabolic channelling of R5P into mycobacterial cell wall 
biosynthetic precursors  
Apart from being a key metabolite in the de novo and salvage pathways of purine and 
pyrimidine biosynthesis, as well as histidine, tryptophan, NAD and NADP metabolism, 
pRpp serves as a high-energy intermediate in the formation of the mycobacterial cell wall 
precursor DPR (Fig. 1) (Scherman et al., 1995). We investigated the conversion of [14C]-
R5P into the cell wall AraT substrate DPA and its precursor, DPR. Assays were 
conducted using membranes prepared from M. smegmatis which provided a source of 
DPPR synthase (Huang et al., 2005), which was necessary to investigate incorporation of 
[14C]-R5P into lipid-linked organic extractable material. When assays were performed 
with just [14C]-R5P and membranes, no radioactive product was detectable in the organic 
phase, as depicted in Figure 3, lane 1. In this instance, all radioactivity remained in the 
aqueous phase of the assay work-up (data not shown). In addition, M. smegmatis P60 (a 
preparation of cell wall material rich in proteins associated with cell wall processes) 
 at University of Birm
ingham
 on February 10, 2011
glycob.oxfordjournals.org
D
ow
nloaded from
 
10 
exhibited no pRpp synthetase activity (Fig. 3, lane 2). When recombinant Mt-PrsA is 
included in the assay, the formation of DPPR and DPR can be clearly observed (Fig. 3, 
lane 3). It is likely that DPPR undergoes enzyme catalysed 5’-dephosphorylation, 
resulting in the formation of DPR. In M. tuberculosis, Rv3807c is an excellent candidate 
for this enzyme since it codes for a putative membrane bound PAP2 phosphatase directly 
adjacent to the DPPR synthase (Rv3806c) (Fig. 1) (Cole & Barrell, 1998). M. smegmatis 
has a direct orthologue of this phosphatase encoded by MSMEG6402, which explains the 
apparent conversion of DPPR to DPR observed in this assay. The combined addition of 
sodium fluoride and sodium tungstate (known phosphatase inhibitors (Stankiewicz & 
Gresser, 1988)) to the assay mix, results in a diminished level of DPR formation and a 
corresponding increase in a band migrating to a lower position on the TLC identified as 
being DPPR (Fig. 3 lane 4). When Mt-PrsA is used in combination with M. smegmatis 
P60, two additional bands can be observed migrating in close proximity to DPR, which 
correspond to the subsequent conversion of DPR to DPX and DPA, by the endogenous 
P60 activity of DprE1 and DrpE2, respectively (Fig. 3, lane 5) (Mikusova et al., 2005). 
Inclusion of sodium fluoride and sodium tungstate dramatically reduced the conversion 
of DPPR to DPA, suggesting that the two-step epimerisation of the C2-OH group of 
ribose by DprE1 and DprE2 occurs after 5’ dephosphorylation (Fig. 3, lane 6). The 
inclusion of ADP to the reaction mix completely ablated the formation of any organic 
extractable material, clearly indicating that ADP inhibition of Mt-PrsA results in the total 
loss of DPPR formation (Fig. 3, lane 7).  
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In a separate experiment, assays were carried out in the presence of a neo-glycolipid 
acceptor [Araf-α(1?5)-Araf-O-(CH2)CH3], which is specific for measuring the activity 
of the cell wall biosynthetic arabinofuranosyltransferases EmbA, EmbB, EmbC and AftB 
(Lee et al., 1997; Seidel et al., 2007), all of which reside in the membrane due to the 
polytopic nature of these GT-C family glycosyltransferases. AraT activity was measured 
after product isolation by organic extraction and analysis by TLC and autoradiography. 
AraT assays carried out in the absence of Mt-PrsA afforded no AraT-dependent product 
formation (Fig. 4, lane 1). Upon addition of Mt-PrsA, two closely migrating bands could 
be observed with the top bad attributed to α(1?5)-Araf transfer to the acceptor by either 
EmbA, EmbB, EmbC (or a combination) and the lower band attributed to β(1?2)-Araf 
transfer resulting from AftB activity (Fig. 4, lane 2), as previously described (Lee et al., 
1997). Addition of the EmbA, EmbB and EmbC inhibitor ethambutol (EMB), resulted in 
the loss of the upper band with only the lower band remaining, this being due to the non-
inhibitory effect of EMB on the terminal β(1?2) capping enzyme, AftB (Seidel et al., 
2007) (Fig. 4, lane 3). As a consequence of allosteric inhibition of Mt-PrsA and the 
resultant loss of in vitro Mt-PrsA-dependent pRpp formation, the inclusion of ADP in the 
assay mixture led to inhibition of any AraT-dependent product formation (Fig. 4, lane 4). 
 
Kinetic characterisation of Mt-PrsA substrates and inhibitors using a continuous 
spectrophotometric assay. 
Due to the rapid enzymic activity of recombinant Mt-PrsA using the radioactive assay 
previously described, we sought to link Mt-PrsA catalysed AMP product release to a 
three-enzyme coupled assay system, thus enabling us to measure NADH oxidation at 340 
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nm in a continuous spectrophotometric assay, which has been described similarly 
elsewhere (Braven et al., 1984). This system (described in Material and Methods) 
enabled us to record detailed measurements of the steady-state enzyme kinetics of Mt-
PrsA. Plotting the steady state reaction velocity (ν) calculated from equation 1, as a 
function of increasing concentrations of R5P at saturating levels of ATP, results in a 
hyperbolic curve displaying Michelis-Menton kinetics (Fig. 5A). Nonlinear regression 
analysis using equation 2 derived a Km of 8.2 µM (± 2.72 Std. Error) for R5P and a Vmax 
of 530 µmol-1.min-1.mg-1 and a specificity constant (Kcat/Km) of 7.43 × 106 M-1.s-1. As 
previously described using the radiochemical assay, Mt-PrsA requires the presence of Pi 
at a concentration of 50 mM for full enzyme activation, which is illustrated in Fig. 5A. 
However, at reduced levels of Pi (5 mM), the subsequent addition of R5P results in 
partial substrate inhibition, an effect that has been observed elsewhere (Willemoes et al., 
2000) (data fitted to equation 3), with little or no activity recorded in the absence of Pi 
(Fig. 5A). This is likely due to Mt-PrsA being incompletely activated by Pi at low [Pi], 
meaning that at low R5P concentrations the relatively high-affinity catalytic site for R5P 
is occupied and normal Micheli-Menton kinetics occur until R5P reaches a concentration 
that results in the occupancy of a second low-affinity inhibitory site which would 
otherwise be occupied by Pi at higher [Pi]. Kinetic analysis of Mt-PrsA with increasing 
ATP concentrations at saturating levels of R5P results in a sigmoidal response showing 
positive cooperativity (Fig. 5b). Data obtained from measuring ν against increasing 
concentrations of ATP at various Pi concentrations was fitted to equation 4. At activating 
levels of [Pi] (50 mM), the S0.5 and Vmax for ATP was calculated as being 62.65 µM (± 
12.04 Std. Error) and 601 µmol-1.min-1.mg-1 (± 66.39 Std. Error) respectively. An 
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apparent Hill-coefficient (n) of 1.68 indicates strong positive cooperativity during 
increasing [ATP]. However, when fitted to equation 4 using nonlinear regression 
analysis, this effect diminishes at low [Pi] resulting in a ν vs [ATP] response with altered 
kinetic constants (Fig. 5b). It has been reported elsewhere that Prs enzymes from other 
organisms are allosterically inhibited by the presence of ADP (Arnvig et al., 1990; 
Eriksen et al., 2000; Gibson et al., 1982; Switzer & Sogin, 1973; Willemoes et al., 2000). 
We measured the effect of ADP on ν as a function of increasing [R5P] and [ATP]. At 
saturating concentrations of ATP, the addition of ADP resulted in non-competitive 
inhibition of Mt-PrsA with a calculated Ki of 320 µM (± 53.51 Std. error) against 
increasing [R5P] (data fitted to equation 5) (Fig. 6a). When we measured the effect of 
ADP on the kinetic response of Mt-PrsA to increasing [ATP] and subsequent fitting of 
the data to equation 6 (Fig. 6b), we calculated a Ki of 522 µM (± 45.78 Std. Error).  
 
Biophysical characterisation of Mt-PrsA: oligomeric state and ligand binding 
studies 
Mt-PrsA homologues from other organisms have been reported to aggregate in solution 
in various homo-oligomeric states, ranging from dimer to octamer (Arnvig et al., 1990; 
Li et al., 2007; Schubert et al., 1975). Using analytical ultracentrifugation, we performed 
a set of sedimentation velocity experiments on Mt-PrsA in the absence or presence of 
R5P, ATP and ADP at a saturating concentrations (Fig. 7). Analysis of each experiment 
by interpretation of the molar mass distribution c(M), indicates that Mt-PrsA in solution 
alone, reaches a dynamic equilibrium between two molecular species with peaks centred 
over ~ 100,000 Da and ~ 205,000 Da, which relate to Mt-PrsA in a trimeric and 
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hexameric aggregation state respectively (Fig. 7, black line). The inclusion of 5 mM R5P 
showed no apparent change in the equilibrium or oligomeric state of Mt-PrsA in solution, 
and the c(M) vs Mw distribution aligned well with that of Mt-PrsA in the absence of 
ligand (Fig. 7, red line). The addition of 5 mM ATP to Mt-PrsA resulted in an altered 
c(M) distribution with a peak centred over ~ 70,000 Da, equating to a Mt-PrsA 
homodimer, and concomitant reduction in the intensity of the hexameric species, as 
compared to Mt-PrsA alone (Fig. 7, blue line). Interestingly, when we performed a 
similar experiment in combination with 5 mM ADP, the ratio of c(M) distribution shifted 
towards an increase in the hexameric state with a corresponding reduction in trimeric 
species (Fig. 7, green line). Mt-PrsA contains within its primary amino acid sequence, 
three naturally occurring tryptophan residues at position Trp 5, Trp 74 and Trp 188. We 
used Intrinsic Tryptophan Fluorescence (ITF) spectroscopy to probe the binding 
properties of R5P, ATP and ADP for Mt-PrsA. We performed a fluorescence emission 
(Femission) scan of Mt-PrsA in solution by recording (Femission) output between 300 and 400 
nm, upon excitation at λ292nm. Mt-PrsA gave a maximum fluorescence emission 
(Femissionmax) at a wavelength of 335 nm, thus providing a basal Femission coordinate for the 
collection of subsequent ITF data. The change in fluorescence emission (∆Femission) was 
calculated by subtracting the Femission (recorded 5 min after each ligand titration) away 
from (Femissionmax), and the data was then plotted against [L]. Nonlinear regression 
analysis of ∆Femission vs [R5P] using equation 7 shows a hyperbolic isothermal ligand 
binding curve for R5P, with a calculated Kd of 24.8 µM (± 6.77 Std. Error) (Fig. 8a). We 
sought to investigate what effect ATP might have on the Kd for R5P, however, the 
inclusion of both ATP and R5P would obviously result in enzyme catalysis and the 
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formation of pRpp and AMP. Due to the relatively high specific activity of Mt-PrsA, the 
addition of R5P and ATP at concentrations required for the effective measurement of 
ligand binding constants by ITF would result in a reaction that would go to completion 
within the 5 min time-frame required to establish binding equilibrium. Therefore, due to 
the stability of the imido-diphophate moity and lack of enzyme-catalysed phosphate 
transfer, we used the ATP analogue 5'-adenylyl-β,γ-imidodiphosphate (AMPPNP) as an 
ATP ligand substitute for binding assays, when carried out in conjunction with R5P. Mt-
PrsA was titrated with increasing [AMPPNP] using identical increments carried out 
during ATP ligand binding experiments. Subsequent nonlinear regression analysis and 
comparison of the ∆Femission vs [AMPPNP] and ∆Femission vs [ATP] plots (data not shown) 
resulted in a strong correlation (R2 = 0.986) as well as extremely similar dissociation 
constants of 28.29 µM (± 0.54 Std. Error) and 31.02 µM (± 0.62 Std. Error) for ATP and 
AMPPNP respectively. With similarly calculated Hill-coefficients (n) of ~4, the almost 
identical binding properties of ATP and AMPPNP for Mt-PrsA allowed us to confidently 
substitute AMPPNP for ATP during binding assays carried out in combination with R5P. 
In this regard, when R5P was titrated against Mt-PrsA in the presence of 5 mM 
AMPPNP, the apparent Kd for R5P decreased to 21.36 µM (± 4.84 Std. Error). This data 
indicates that the Mt-PrsA-AMPPNP complex exhibits a slightly higher affinity for R5P 
when compared to Apo-Mt-PrsA (Fig. 8a). In the reverse experiment where ∆Femission vs 
[AMPPNP] was measured in the presence or absence of 5 mM R5P (Fig. 8b), the affinity 
of Mt-PrsA-R5P for AMPPNP increased slightly, as is evident from the reduction in Kd 
to 28.22 µM (± 0.54 Std. Error) and an increase in the Hill-coefficient (n) to 5 by a value 
of 1. In light of the previous AUC experiment, which suggests that the addition of ADP 
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induces a shift towards Mt-PrsA hexamerisation, we performed an ITF experiment by 
tritrating Mt-PrsA with increasing  [ADP] (Fig. 9a). Unsurprisingly, the ∆Femission vs 
[ADP] plot displays a sigmoidal cooperative binding response with an apparent Kd of 
512.6 µM (± 39.57 Std. Error) and a Hill-coefficient of 2. Since ATP and ADP bind to 
Mt-PrsA at separate sites, and induce very different aggregation states, the apparent ~2 
fold difference in the Fmax recorded for ATP and ADP is most likely due to the differing 
effects each of these ligands have on the chemical environments surrounding the 
tryptophan residues providing the source of Femission in Mt-PrsA (Eriksen et al., 2000). 
The inclusion of ADP at two different concentrations (0.1 and 2.0 mM) in separate ITF 
[ATP] ligand binding assays, causes a significant increase in the apparent Kd of ATP for 
its Mt-PrsA binding site (KdATP = 31.22 µM and 90.1 µM at a concentration of 0.1 and 2.0 
mM ADP respectively), clearly illustrating allosteric inhbition of Mt-PrsA-ATP complex 
formation (Fig. 9b). The change in the slope of the curve as a function of [ATP] in 
separate ITF experiments carried out at increasing ADP concentrations, clearly illustrates 
a reduction in the homotropic cooperative binding of ATP for Mt-PrsA, which was 
confirmed by calculating the resultant Hill-coefficients (Fig. 9b). The ligand binding 
properties of ADP for Mt-PrsA, in the presence of ATP, compares well with the 
inhibition constant calculated for ADP [Ki = 522 µM (± 45.78 Std. Error)] obtained from 
kinetic analysis of ν vs [ATP] at saturating [R5P] (Fig. 6b). 
 
Structural model of Mt-PrsA 
An alignment of Mt-PrsA with its related Corynebacterineae PrsA orthologues as well as 
othet bacterial Prs homologues from Bacillus subtilis (Bs_PrsA), Escherichia coli 
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(Ec_PrsA) and Streptomyces coleicolor (Sc_PrsA), and the three human Prs isoforms 
(Human_PrsA1-3) clearly illustrates the high level of primary sequence conservation 
between all variants (Fig. 10). Mt-PrsA shares very high sequence identity with its 
Corynebacterineae counterparts (92 % Mycobacterium leprae, 87 % Mycobacterium 
smegmatis and 71 % Corynebacterium glutamicum) and a moderate level of sequence 
identity with Mt-PrsA homologues in S. coleicolor (61 %), E. coli (43 %) and B. subtilis 
(43 %). Interestingly, the three human Prs isoforms also share 40 % sequence identity 
with Mt-PrsA. Both of the human type 1 and B. subtilis pRpp synthetase X-ray crystal 
structures have been solved (Eriksen et al., 2000, Sheng et al., 2007). Each of these 
structures were solved in the Apo form and in complex with AMP, which is located in the 
ATP binding pocket of the active site. Interestingly, the Bs-PrsA structure was solved in 
complex with an additional molecule of ADP, thus revealing its position and mode of 
action in the allosteric regulatory site of the enzyme (Eriksen et al., 2000). Since Mt-PrsA 
shares highest sequence homology with Bs-PrsA, we constructed a homology model of 
Mt-PrsA using the structure of Bs-Prs in complex with AMP and ADP as a template 
(Eriksen et al., 2000) (Fig. 11). Using crystallographic symmetry data from the Bs-Prs 
structure, we arranged the Mt-PrsA homology model into its hexameric form (Fig. 11a). 
Each monomer is composed of two subunits, which is related by a 3-fold axis 
perpendicular to an additional 2-fold planar rotational symmetry. Many of the residues 
involved in binding at the interface between monomers are well conserved, with notable 
differences highlighted by the position of red spheres in Fig. 11a. With only a few 
exceptions, the sequence alignment of Mt-PrsA and Bs-Prs indicates that most of the 
residues involved in enzyme catalysis and allosteric regulation are conserved which, in 
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turn, are suitably positioned in the Mt-PrsA homology model compared to Bs-Prs. A 
noteworthy difference in the Mt-PrsA catalytic site is the presence of Asn45, which is 
arranged to form contacts with the ADP ligand (Fig. 11b). In the Bs-Prs structure, the 
equivalent residue is Asp42. In addition, further comparison of the two structures 
suggests that the Mt-PrsA homology model retains all of the important residues required 
for the regulatory site, apart from Gly88 (Ala85 in Bs-Prs), which participates in the 
formation of contacts to ADP with a neighbouring Ser89 (Fig. 11b). An interesting 
observation in the model of Mt-PrsA is the presence of His109 in the “flexible loop” 
formed by Mt-PrsA residues Lys108 – Arg112. Ala106 is the equivalent residue in Bs-
Prs, and it appears to play little if no part in binding or coordination of the ADP ligand. 
This flexible loop region, which contains many conserved residues (Fig. 10), has been 
identified as displaying some of the largest variation in backbone conformation, and the 
conformational changes that occur upon substrate binding are considered to be important 
for catalysis (Eriksen et al., 2000). The presence of a His residue in the Mt-PrsA flexible 
loop region might allow for multiple hydrogen bonding opportunities between His109 
and the ATP substrate in the catalytic site (Fig. 11b). Gly111 is another conserved residue 
located in the flexible loop of mycobacterial PrsA enzymes, which in the majority of 
other bacterial homologues, is typically replaced by a Ser that makes H-bond interactions 
with the α-phosphate of ADP in the allosteric site (Fig. 11c). Both the Human-PrsA1 and 
Bs-PrsA homodimers are stabilised by a salt bridge at the N-terminal interface formed 
between two conserved residues (Asn114 and Asp139, and Asn120 and Asp145 
respectively) (Eriksen et al., 2000, Sheng et al., 2007). From the sequence alignment and 
Mt-PrsA homology model, it is worth noting that the equivalent Asn residue is replaced 
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by an aspartic acid (Asp122) which would sit in close proximity to Asp147. Therefore, it 
is reasonable to assume that unlike Human-PrsA1 and Bs-PrsA, a salt bridge does not 
occur at the Mt-PrsA dimer interface. Interestingly, the Human-PrsA1 Asn114 (Asp122 
in Mt-PrsA) is often mutated to a Ser in the cells of patients suffering from gout (Becker, 
et al., 1995). It has been reported that the molecular mechanism behind the 50% increase 
in N114S mutant enzyme activity is caused by a disruption of a salt bridge, which would 
otherwise stabilises the dimer interface (Liu et al., 2009).  
 
Discussion 
The presence of D-arabinose in living organisms is rarely observed. Whilst the utilisation 
of D-arabinopyranose seems to be confined to glycoconjugate formation in 
trypanosomatid parasites (Turnock & Ferguson, 2007), arabinose in the furanose 
configuration (Araf) is exclusively used by bacteria in the formation of cell surface 
polysaccharides and the biosynthesis of glycolipid antigens. Members belonging to the 
Corynebacterineae, such as M. tuberculosis and C. glutamicum, contain large quantities 
of Araf in the form of arabinan, which in turn, is covalently attached to galactan and 
mannan, thus forming AG and LAM respectively. Whilst LAM exerts its biological 
activity by subverting the host immune response, the primary function of AG is to 
provide a highly branched molecular scaffold, linking the murine sacculus to the 
hydrophobic mycolate layer. Since arabinan is an essential component of the TB cell wall 
and is targeted by treatment with EMB, other enzymes involved in its formation might 
present themselves as potential putative drug-targets. In this regard, DPPR synthetase 
(Rv3806c) is a novel enzyme catalysing the transfer of pRpp to decaprenol-1-
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monphosphate forming DPPR (Fig. 1) and represents the first committed step towards the 
biosynthesis of DPA (an exclusive cell wall AraT substrate) and as a consequence of its 
genetic disruption in C. glutamicum (a model organism used to study M. tuberculosis cell 
wall physiology), affords a phenotype displaying retarded growth, and a severely altered 
cell wall composition which is completely deficient in arabinan (Alderwick et al., 2005). 
In addition, DprE1 (Rv3790) has been shown to be the molecular target of 
benzothiazinones, a new class of antimycobacterial agents, which can effectively kill 
MDR and XDR strains of TB by blocking the C2-OH epimerisation of DPR to DPA 
(Makarov et al., 2009). Some of the current front line drugs used to treat TB include cell 
wall inhibitors. However, the incidence of MDR and XDR-TB cases is alarmingly high 
and continues to rise (Madariaga et al., 2008). Since the M. tuberculosis cell wall is a 
valid drug target, we must continue to investigate the physiology, biochemistry and 
metabolic pathways involved in its assembly, to assist our efforts of developing new anti-
TB therapies. However, non-dividing drug-tolerant populations of “persistent” TB bacilli 
fail to be eradicated from the host, giving rise to a latent infection as result of subsequent 
granuloma formation (Barry et al., 2009). Inhibition of cell wall biosynthetic processes of 
TB bacilli responsible for latent infections is of no consequence, this being due to the fact 
that persistent TB bacilli are not undergoing active cell growth and division. However, 
these “dormant” TB-bacilli still require a basal level of “energy” metabolites in order to 
maintain critical cellular functions (Koul et al., 2008). 
 
pRpp is a central metabolite ubuiquitous in nature providing a high-energy substrate for 
the biosynthesis of histidine, tryphophan, NAD, NADP and both the de novo and salvage 
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pathways involved in nucleoside metabolism (Hove-Jensen, 1988) (Fig. 1). In addition to 
these central metabolic processes, the Corynebacterineae have evolved a unique pathway 
in which pRpp is siphoned into cell wall arabinan biosynthesis (Fig. 1). In M. 
tuberculosis, Mt-PrsA is entirely responsible for the provision of pRpp and its cellular 
function bridges five different metabolic pathways (Fig. 1). The omphalic nature of Mt-
PrsA places a heavy burden on its biological function, especially during cell growth and 
division, when the cellular requirement for pRpp increases significantly. In this study, we 
describe the biochemical characterisation of Mt-PrsA, which displays the highest 
recorded specific activity for a pRpp synthetase of 530 µmol-1.min-1.mg-1. The Km for 
R5P was calculated to be in the sub-micromolar range of (8.2 µM), suggesting a rapid 
enzyme turnover with a calculated specificity constant (Kcat/Km) of 7.4 × 106 M-1.s-1. This 
relatively high efficiency of Mt-PrsA fits well with the physiological function of the 
enzyme during cell wall biosynthesis, considering the increased demand for pRpp that is 
required for antecedent DPA biosynthesis. Mt-PrsA displays clear homotropic 
cooperativity for ATP, with an apparent S0.5 62.65 µM, which is extremely low 
considering the intracellular concentration of ATP is considered to be between 3 – 5 mM. 
The homology model generated for Mt-PrsA contains many structural features of other 
pRpp synthetases that have been solved to date. The majority of the active site residues 
modelled in Mt-PrsA are conserved with those from other Mt-PrsA homologues, and it 
appears that the appropriate configuration of amino acid side chains compares well with 
the B. subtilus structure. This is also the case for the regulatory site in which ADP binds 
to allosterically modulate the enzyme. However, an interesting observation is the 
presence of His109 in the flexible loop region of Mt-PrsA, a residue exclusively 
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conserved within members of the Corynebacterineae. Considering the close proximity of 
His109 to both the catalytic and regulatory sites of Mt-PrsA, and its potential to make 
direct contacts with both ATP and ADP ligands, the presence of this conserved His in the 
flexible region of mycobacterial pRpp synthetases might provide some explanation for 
the relatively high Kcat. pRpp synthetase superactivity is observed in human type-1 
N114S mutants (Becker, et al., 1995). This is increase in activity is a result of the loss of 
a salt bridge formed between two monomers which induces small but significant changes 
to the catalytic and regulatory site of the enzyme (Liu et al., 2009). Interestingly, the 
homology model of Mt-PrsA suggests that a slat bridge between the equivalent residues 
does not occur thus reducing the stability of the dimer interface. In mycobacteria, the 
biosynthesis of pRpp is required at a rate which is sufficient to not only supply central 
metabolic processes, such as de novo nucleoside biosynthesis, but also at a necessary 
level to meet the increased demands for pRpp during cell wall biosynthesis (Scherman et 
al., 1995; Scherman et al., 1996). It seems plausible that pRpp synthetases from 
Corynebacterineae species have evolved a highly efficient version of the enzyme to 
account for the increased metabolic flux of pRpp, during various physiological states. 
pRpp synthetases in other organisms undergo stringent control by virtue of allosteric 
modulation from ADP. In this regard, Mt-PrsA also appears to be no different, displaying 
clear inhibition of enzyme activity between 0.5 - 2.0 mM ADP. When taken together, the 
data relating to ADP inhibition and the subsequent complex formation with Mt-PrsA, 
suggests that the mechanism employed for allosteric regulation of Mt-PrsA by ADP, is 
through the formation of a Mt-PrsA hexamer (Arnvig et al., 1990). This net increase in 
Mt-PrsA hexamer oligimerisation suggests that the efficacy of ATP for its Mt-PrsA 
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catalytic site decreases, as a consequence of ADP allosteric modulation. The three human 
PrsA isoforms share a very high sequence identity (91 - 95 % between all three), however 
the subtle differences that do occur appear in regions of the enzyme which are important 
for catalysis and allosteric regulation. Inhibition studies using two 
aminopyrimidopyrimidine nucleotide analogues 4-methoxy-8-(β-D-ribofuranosylamino)-
pyrimido-[5,4-d]-pyrimidine (MRPP) and 4-amino-8-(β-D-ribofuranosylamino)-
pyrimido-[5,4-d]-pyrimidine (ARPP) show differential levels of inhibition of human 
pRpp synthetases (Fry et al., 1995). Carbocyclic analogues of ribose-5-phosphate are 
another class of compounds which show differential inhibition when tested against 
Salmonella typhimurium, B. subtilis and human pRpp synthetases (Parry et al., 1996). In 
this regard, the development of a similar library of compounds targeted for the specific 
inhibition of Mt-PrsA might warrant further investigation. Understanding metabolic 
pathways that are essential for persistent TB infections, such as mycobacterial energy 
metabolism, in combination with pathways involved in cell wall assembly seems a 
plausible strategy for the development of new anti-mycobacterial drugs. 
 
Materials and Methods 
Bacterial strains cloning procedures 
Escherichia coli Top 10 cells (Invitrogen) were used to propagate plasmids during all 
cloning experiments and the over-expression of Mt-PrsA was carried out in E. coli C41 
(DE3) (Lucigen). Phusion DNA polymerase was purchased from New England Biolabs 
and all restriction enzymes and T4 DNA ligase were purchased from fermentas. 
Oligonucleotides were purchased from eurofins-MWG and PCR fragments were purified 
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using QIAquick gel extraction kit (Qiagen). Plasmids were purified using the Qiaprep 
purification kit (Qiagen). 
 
Generation of C. glutamicum prsA-null mutant 
For the genomic disruption of NCgl0945 (Cg-prsA), we constructed the plasmid 
pK18mob-Cg-prsA-int, using the primer pair pNCgl0945_intfor 
(GCGAGCCAATTTCTGCTCGC) and pNCgl0945_intrev 
(GACAACCTGGTTTGCTACCTC) to amplify C. glutamicum WT chromosomal DNA. 
The resulting DNA fragment was treated with AvaI/KpnI, and ligated into the non-
replicative vector pK18mob (Schafer et al., 1994), which was similarly treated with 
AvaI/KpnI. The DNA integrity of the resulting construct pK18mob-Cg-prsA-int was 
confirmed by sequencing and used for transformation of C. glutamicum by 
electroporation and selected for resistance to kanamycin at 25 µg/ml on BHIS medium. 
 
 
 
Construction of Mt-PrsA expression vector 
The 981-bp coding region for Mt-PrsA (annotated as Rv1017c) in the M. tuberculosis 
H37Rv genome was amplified by PCR using the following primer pairs (restriction sites 
underlined) GATCGATCGCTAGCTTGAGCCACGACTGGACCGATAATCGC 
(forward) and GATCGATCCTCGAGTGCGTCCCCGTCGAAAAGTCCTGTTAC 
(reverse). This DNA fragment was restricted with the appropriate enzymes (NheI and 
XhoI) and ligated into pET23b digested with identical enzymes, thus yielding pET23b-
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Mt-prsA, which encodes for an C-terminal His6-tagged protein. DNA sequencing and 
construct verification was carried out at the University of Birmingham School of 
Bioscience Genomics Facility. 
 
Expression and Purification of Mt-PrsA 
E. coli C41 (DE3) cells were transformed with pET23b-Mt-prsA and selected on LB agar 
supplemented with 100 µg/mL amplicillin. Recombinant E. coli cells harbouring 
pET23b-Mt-prsA were used to inoculate an overnight of 5mL LB supplemented with 100 
µg/mL amplicillin. This overnight was then used to inoculate 2 x 1 L LB medium 
supplemented with 100 µg/mL amplicillin and incubated at 37 °C with shaking until A600 
reached 0.5. IPTG was then added at a final concentration of 1 mM and growth continued 
for an additional 12 h at 16 °C with shaking. Cells were harvested by centrifugation at 
6000g for 15 mins and washed with 20 mL phosphate buffered saline. Pellets were then 
frozen until further use. For purification, one pellet was thawed and re-suspended into 50 
mM KH2PO4 (pH 7.9), 300 mM NaCl, 20 mM imidazole, one complete protease inhibitor 
cocktail tablet (Roche) and DNAse and RNAse both at a final concentration of 50 µg/mL. 
The cell suspension was disrupted by sonication at a pulse rate of 30 sec ON and 30 sec 
OFF for a total of 10 cycles. The cell slurry was centrifuged for 30 min, 28000g at a 
temperature of 4 °C. The supernatant was collected and passed over a 5 mL HiTrap Ni2+-
NTA agarose column (GE Healthcare), which was previously equilibrated with into 50 
mM KH2PO4 (pH 7.9), 300 mM NaCl and 20 mM imidazole. Elution occurred via a 
stepwise gradient of 50 – 500 mM imidazole in 50 mM KH2PO4 (pH 7.9), 300 mM NaCl 
and 10 mL fractions were collected. Mt-PrsA was detected to be present and ~ 98 % pure 
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in the 250 mM imidazole fraction, as determined by 12% SDS-PAGE analysis. The 250 
mM imidazole fractions of Mt-PrsA was first dialysed against 2 L KH2PO4 (pH 7.9), 150 
mM NaCl, 5 mM EDTA and 1 mM DTT at 4 °C and then against 2 L KH2PO4 (pH 7.9), 
150 mM NaCl, 1 mM DTT and 10 % glycerol. After dialysis, the protein concentration 
was determined using the bicinchoninic acid procedure (Pierce) and bovine serum 
albumin as a standard. 
 
Preparation of [14C]-U-D-ribose-5-phosphate 
We prepared a source of [14C]-U-D-ribose-5-phosphate ([14C]-R5P) using a modified 
process as described in (Boss et al., 1984),for the subsequent use in Mt-PrsA assays. 100 
µCi of [14C]-U-D-glucose (100 µl in 70 % ethanol) (ARC radiochemicals) was dried in 
14 ml glass tube under compressed nitrogen and then resuspended in 500 µl of 50 mM 
KH2PO4 (pH 7.9), 150 mM NaCl, 5 mM MgCl2 and 0.5 mM MnCl2. 20 µl of ATP (100 
mM stock) and 20 µl of NADP (100 mM stock) was added to the suspension. 20 µl of 
hexokinase/glucose-6-phosphate dehydrogenase enzyme mix (Roche) was added and 
incubated at 37 °C for 15 mins. A few grains of 6-phosphogluconic dehydrogenase 
(Sigma) and a further 20 µl of NADP (100 mM stock) was added and incubated for 15 
mins at 37 °C. A few grains of phosphoribose mutase (Sigma) was added to the reaction 
mix and incubated for a further 15 mins at 37 °C followed by another addition of 20 µl 
NADP (100 mM stock) and final incubation at 37 °C for 15 mins. The reaction mix was 
then diluted with H2O to a final volume of 3 mL and passed through a 10 kDa MWCO 
centrifugal filtration device (Millipore). The filtrate (~ 3 mL) was then loaded onto a 3 
mL LC-SAX anion exchange cartridge (Supelco) pre-equilibrated with H2O. The column 
 at University of Birm
ingham
 on February 10, 2011
glycob.oxfordjournals.org
D
ow
nloaded from
 
27 
was then washed three times with 3 mL H2O. The column was then washed with a 100-
1000 mM stepwise gradient of sodium acetate (3 mL fractions of 100 mM increments). 
Each fraction (1 µl) was applied to a glass-backed PEI-cellulose TLC plate and 
developed in 0.85 M KH2PO4 (pH 3.4). After drying, the TLC plate was exposed 
overnight to a Kodak autoradiography film for visualisation of radioactive phospho-
sugars. [14C]-R5P eluted as a single band (as compared to known standards) in the 200 
mM sodium acetate fraction with a specific activity of 33333 cpm/µl.  
 
Radiochemical assay of Mt-PrsA activity 
The enzymatic activity of Mt-PrsA was determined by monitoring the transfer of PPi 
from ATP to the C1-OH group of enzymaticaaly synthesised [14C]-R5P forming 
p[14C]Rpp and AMP. The basic reaction mix contained 50 mM KH2PO4 (pH 7.5), 150 
mM NaCl, 1mM DTT, 10 % glycerol, varying amounts of [14C]-D-R5P [stored in 200 
mM sodium acetate, (33333 cpm/µl)], 2 mM ATP and 30 µg Mt-PrsA (15 µl) in a final 
volume of 100 µl. On occasions, MgCl2, MnCl2, CaCl2, ADP and EDTA were included 
in the reaction mix either separately or combination, all at a final concentration of 2 mM. 
Reactions were initiated by the addition of Mt-PrsA and incubated at 37 °C for 10 mins. 
Reactions were quenched by the addition of 10 µl 0.4 M formic acid. The mixture (1.1 
µl) was applied to a glass-backed PEI-cellulose TLC plate and developed in 0.85 M 
KH2PO4 (pH 3.4). After drying, the plate was inspected for radioactive spots by either 
exposure to a Kodak film followed by autoradiography or a PhosphorImager (Molecular 
Dynamics). All experiments were repeated in triplicate. 
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Metabolism of [14C]-R5P into mycobacterial cell wall biosynthetic precursors  
Membranes (containing membrane bound enzymes involved in lipid-linked cell wall 
biosynthetic processes) and “P60” (a percoll-derrived cell free fraction rich carbohydrate 
and enzymes associated with cell wall processes as described in (Besra et al., 1997)) 
fractions from M. smegmatis were prepared as described previously (Alderwick et al., 
2006a; Besra et al., 1997; Lee et al., 1997) and resuspended in buffer A [50 mM MOPS 
(pH 7.9), containing 5 mM β-mercaptoethanol and 10 mM MgCl2] to a final 
concentration of 15 mg/ml and 10 mg/ml for membrane and P60 fractions, respectively. 
50 µg of decaprenol-1-monophosphate (Larodan Lipids, Malmo, Sweeden) (5 mg/ml 
stored in CHCl3/CH3OH (2:1, v/v)) was dried in a 1.5 ml eppendorf tube under 
compressed nitrogen and was resuspended by the addition of 10 µl of a solution of 50 
mM MOPS (pH 7.9), 50 mM KH2PO4, 150 mM NaCl, 1 mM MnCl2, 1 mM MgCl2, 1 
mM DTT and 1% IgePal CA-630 (Sigma) followed by bath sonication. The basic assay 
mix consisted of 0.5 mg M. smegmatis membranes (33 µl), 2 mM ATP, 50 mM MOPS 
(pH 7.9), 50 mM KH2PO4, 150 mM NaCl, 1 mM MnCl2, 1 mM MgCl2, 1 mM DTT, 
100,000 cpm [14C]-R5P (3 µl) in a final volume of 200 µl. NaWO4 and NaF as well as 
ADP were included in separate assay reactions at a final concentration of 2 mM for all 
inhibition studies. 0.5 mg of M. smegmatis P60 (50 µl) was added a where appropriate. 
Reactions were initiated by the addition of 30 µg of Mt-PrsA (15 µl) and incubated at 37 
°C for 30 mins. Assays were quenched by the addition of 1.33 ml of CHCl3/CH3OH (1:1, 
v/v), mixed for 30 mins and centrifuged at 27,000g to remove precipitated proteiacous 
material. The supernatent was removed to a separate tube and combined with 670 µl 
CHCl3 and 287 µl H2O, mixed for 15 mins and centrifuged for 5 mins at 4000g to form a 
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biphase. The lower organic phase was removed and washed twice with 765 µl 
CHCl3/CH3OH/H2O (3:47:48, v/v/v) and then dried under compressed nitrogen. Samples 
were the resuspended in 100 µl CHCl3/CH3OH (2:1, v/v) and an aliquot subject to TLC 
analysis using silica gel plates (5735 silica gel 60F254, Merck) developed in 
CHCl3/CH3OH/CH3COONH4/NH4OH/H2O (180:140:9:9:23 v/v/v/v/v) and visualised by 
autoradiography by exposure of TLCs to X-ray film (Kodak X-Omat) as described in 
(Mikusova et al., 2005). 
 
Metabolism of [14C]-R5P into mycobacterial cell wall biosynthetic precursors and 
the subsequent AraT-dependent transfer to a neo-glycolipid acceptor. 
Membranes and P60 from M. smegmatis were prepared as described above. The neo-
glycolipid acceptor used in this study was the disaccharide α-D-Araf-(1→5)-α-D-Araf-O-
(CH2)7CH3 (Ara2) which has been previously reported by us (Lee et al., 1997; Seidel et 
al., 2007). In individual assays, the Ara2 acceptor 8 µl (stored in CHCl3/CH3OH, 2:1, v/v 
at 20 mM) and 50 µg of decaprenol-1-monophosphate (Larodan Lipids, Malmo, 
Sweeden) (5 mg/ml stored in CHCl3/CH3OH (2:1, v/v)) was aliquoted into 1.5 ml 
eppendorf tubes and dried under nitrogen. The AraT assay was carried out as described 
previously (Lee et al., 1997; Seidel et al., 2007) with modifications. IgePalTM (Sigma-
Aldrich) was added (0.1%, v/v) with the appropriate amount of buffer A (final volume 
100 µl). Tubes were sonicated for 15 min to resuspend lipid linked substrates and then 
mixed with the remaining assay components, which included 0.5 mg M. smegmatis 
membranes (33 µl), 0.5 mg M. smegmatis P60 (50 µl), 30 µg Mt-PrsA (15 µl), 1 mM 
ATP, 1 mM NADP and in some cases EMB (100 µg/ml). Assays were incubated for 1 h 
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at 37°C and quenched by the addition of 633 µl CHCl3/CH3OH (1:1, v/v). After mixing 
and centrifugation at 27000g for 15 min at 4°C, the supernatant was removed and dried 
under nitrogen. The residue was then resuspended in 700 µl of CH3CH2OH/H2O (1:1, 
v/v) and loaded onto a 1 ml LC-SAX strong anion exchange cartridge (Supelco), pre-
equilibrated with CH3CH2OH/H2O (1:1, v/v). The column was washed with 2 ml 
CH3CH2OH and the eluate collected, dried and partitioned between the two phases 
arising from a mixture of n-butanol (3 ml) and water (3 ml). The resulting organic phase 
was recovered following centrifugation at 3,500g and the aqueous phase again extracted 
twice with 3 ml of water-saturated n-butanol. The pooled extracts were back-washed 
twice with n-butanol-saturated water (3 ml). The n-butanol fraction was dried and 
resuspended in 200 µl butanol. The extracted radiolabeled material was quantified by 
liquid scintillation counting using 10 % of the labelled material and 5 ml of EcoScintA 
(National Diagnostics, Atlanta). The incorporation of [14C]-Araf into Ara2 was 
determined by subtracting counts present in control assays (incubations in the absence of 
acceptor). The remaining labelled material was subjected to TLC using 
CHCl3:CH2OH:H2O:NH4OH (65:25:3.6:0.5, v/v/v/v) on aluminium-backed silica gel 
plates (5735 silica gel 60F254, Merck) and products were visualised by autoradiography, 
exposing the TLCs to X-ray film (Kodak X-Omat). 
 
Continuous enzyme-coupled spectrophotometric assay and kinetic characterisation 
of Mt-PrsA substrates. 
By using a modified assay described by Braven et al., (1984), the amount of AMP 
produced as a product of Mt-PrsA catalysis was measured indirectly by monitoring the 
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decrease in absorbance of NADH at 340 nm via the following enzyme couple: 1. R5P + 
ATP ? pRpp + AMP, catalysed by Mt-PrsA; 2. AMP + ATP ? 2 ADP, catalysed by 
myokinase (MK); 3. 2 ADP + 2 phosphoenolpyruvate (PEP) ?  2 pyruvate + 2 ATP, 
catalysed by pyruvate kinase (PK) and 4. 2 pyruvate + 2 NADH + 2 H+ ? 2 lactate + 2 
NAD+, catalysed by lactate dehydrogenase (LDH). This perpetual enzyme couple 
immediately replenishes the pool of ATP and results in a stoichiometry of  1 mole of 
NADH oxidised by lactate dehydrogenase for every 2 moles of AMP produced by Mt-
PrsA. The following formula was used to calculate the rate of reaction thus allowing for a 
detailed kinetic characterisation of Mt-PrsA, 
 
v = (∆A.s-1)/2 × 6220 M-1 (Equation 1) 
 
where ν is the steady-state rate of the reaction, ∆A is the change in absorbance at 340 nm 
and 6220 M-1 is the molecular extinction coefficient of NADH measured at 340 nm. The 
reaction mixture comprised of 50 mM KH2PO4 (pH 7.9), 150 mM NaCl, 0.25 mM DTT, 
2 mM MnCl2, 2.0 mM PEP, 1.0 mM NADH, and 5 mM NaF, MK, PK and LDH were 
added to the mix all at a concentration of 0.2 units/mL. Variable amounts of ATP, R5P 
and ADP were added to the reaction mix for enzyme kinetic and inhibitor studies. 
Reactions were initiated by the addition of R5P. All kinetic experiments were carried out 
in triplicate (from three different independent protein preparations of purified 
recombinant Mt-PrsA) and data points (calculated mean) and standard errors (± Std. 
Error) relating to enzyme steady state velocities (ν) (µmol.min-1.mg-1) derived from 
equation 1 under various substrate and inhibitor conditions, was analysed by nonlinear 
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regression analysis and fitted to the appropriate equation (2-6) using the GraphPad Prism 
software package. Equation 2 is the Michelis-Menten equation for hyperbolic substrate 
saturation kinetics and equation 3 applies to nonlinear regression of substrate inhibition. 
Equation 4 is the Hill equation for calculating cooperative substrate saturation kinetics, 
equation 5 applies to noncompetitive enzyme inhibition of a hyperbolic enzyme response 
and equation 6 is derived from combining equations 4 and 5 to give an expression for 
noncompetitive enzyme inhibition of a cooperative sigmoidal response to increasing 
substrate concentrations. 
 
ν = Vmax × S / (Km + S)    (Equation 2) 
ν = Vapp × S / [Km + S × (1 + S/Ki)]    (Equation 3) 
ν = Vapp × Sn / (S0.5n + Sn)     (Equation 4) 
ν = Vapp × S / [Km(1 + I/Kis) + S(I + I/Kii)]   (Equation 5) 
ν = Vapp × Sn / [S0.5n (1 + I/Kis) + Sn(1 + I/Kii)] (Equation 6) 
 
where Vmax is the maximum enzyme velocity, Vapp is the apparent maximal enzyme 
velocity, S is the concentration of the substrate being varied, I is the inhibitor 
concentration, Km is the apparent Michelis-Menten constant for S, S0.5 is the half-
saturation concentration for S, n is the apparent Hill-coefficient for S, Kis and Kii are the 
dissociation constants of the [I], for E and ES respectively. 
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Analytical ultracentrifugation  
Sedimentation velocity experiments were performed using a Beckman Optima XL-A 
analytical ultracentrifuge equipped with absorbance optics. Mt-PrsA (dialysed into 50 
mM KH2PO4 (pH 7.9), 300 mM NaCl, 1 mM DTT) was loaded into cells with two 
channel Epon centre pieces and quartz windows. A total of 100 absorbance scans (280 
nm) were recorded  (40,000 rpm, 4°C) for each sample, representing the full extent of 
sedimentation of the sample. Data analysis was performed using the SEDFIT software 
fitting a single friction coefficient (Schuck, 2004). 
 
Intrinsic Tryptophan Fluorescence spectroscopy 
Intrinsic tryptophan fluorescence experiments were carried out using a PTI 
QuantaMasterTM 40 spectrofluorimeter and data recorded using FeliX32 software. The 
excitation wavelength was set at 292 nm and the fluorescence emission (Femmison) spectra 
was recorded between 300 – 400 nm for each ligand aliquot added to a 200 µl solution 
containing 70 µM Mt-PrsA 50 mM KH2PO4 (pH 7.9), 150 mM NaCl, 0.25 mM DTT, 2 
mM MnCl2 was used as a buffer for the measurement of R5P, ATP and AMPPNP ligand 
binding (or a combination) to Mt-PrsA. A plot of the change in fluorescence emission 
(∆Femisson) intensity at λ335nm vs. [L] was fitted to equation 7 for R5P, equation 8 for ATP 
and ADP for independent additions, equation 9 for R5P in combination with AMPPNP 
and equation 10 for ATP and ADP in combination using GraphPad Prism software. 
 
∆Femission = Fmax × L / (Kd + L)      (Equation 7) 
∆Femission = Fmax × Ln / (Kdn + Ln)      (Equation 8) 
 at University of Birm
ingham
 on February 10, 2011
glycob.oxfordjournals.org
D
ow
nloaded from
 
34 
∆Femission = Fmaxa × La / (Kd + La) + Fmaxb × Lnb/ (Kdnb + Lnb)   (Equation 9) 
∆Femission = Fmaxa × Lna/ (Kdna + Lna) + Fmaxb × Lnb/ (Kdnb + Lnb)  (Equation 10) 
 
where Fmax indicates the maximum change in fluorescence emission, Kd is the 
concentration of ligand required to achieve half maximum fluorescence, L is the 
concentration of ligand and n is the Hill-coefficient. The suffixes a and b relate to the 
relative parameters determined for two separate ligands included in a binding assay. 
 
Generation of a Mt-PrsA homology model 
A homology model of the molecular structure of Mt-PrsA was derived based on the 
crystal structure of B. subtilus Prs (Eriksen et al., 2000). Models were obtained from 
several Web-based moedelling servers, including SWISS-MODEL (Schwede et al., 
2003), Geno3D (Combet et al., 2002) and 3D-JIGSAW (Bates et al., 2001). The 
homology models were analysed in comparison to the the Bs-Prs structures in complex 
with SO4- or mADP (PDB entry 1DKR and 1DKU (Eriksen et al., 2000)). 
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Figure Legends 
 
Figure 1. Proposed metabolic pathway depicting the importance of Mt-PrsA for the 
generation of pRpp in M. tuberculosis. R5P is generated via the catabolism of glucose 
through the pentose phosphate pathway, a process ubiquitous throughout nature. Like all 
pRpp synthetase enzymes, Mt-PrsA catalyses the transfer of pyrophosphate from ATP to 
the C1-OH group of R5P forming pRpp and AMP. In a process unique to members 
belonging to the Corynebacteriaceae, such as M. tuberculosis, pRpp is utilised as the sole 
metabolic intermediate in the formation of DPA, which is a crucial substrate required for 
mycobacterial cell wall assembly. (DP) decaprenol-1-monophosphate, (DPA) 
decaprenol-1-monophosphoarabinose, (DPR) decaprenol-1-monophosphoribose, (DPPR) 
decaprenol-1-monophosphoribose-5-phosphate, (DPX) decaprenol-1-monophosphoryl-2-
keto-β-erythro-pentofuranose, (pRpp) phosphoribosyl-1-pyrophosphate, (R5P) ribose -5-
phosphate. 
 
Figure 2. Time course assay showing Mt-PrsA catalysed formation of p[14C]Rpp 
from [14C]R5P and ATP. Assays contained Mt-PrsA, 50 mM Pi, 2mM ATP 
supplemented with either 2 mM Mg2+, Mn2+ or Ca2+ as illustrated in panel A, and in the 
presence of ADP at a final concentration of 2 mM in panel B. Assays were incubated at 
37 °C and aliqouts were removed from the assay mix at 0, 10, 30 and 60 seconds and the 
reactions halted by quenching with addition of formic acid. Samples were applied to a 
glass-backed PEI-cellulose TLC plate and developed in 0.85 M KH2PO4 (pH 3.4). The 
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plate was inspected for radioactive spots relating to p[14C]Rpp and [14C]R5P by 
autoradiography through the exposure of TLCs to X-ray film (Kodak X-Omat). 
 
Figure 3. Analysis of Mt-PrsA dependent [14C]-R5P incorporation into the M. 
smegmatis arabinofuranosyltransferse substrate DPA via p[14C]Rpp. The basic 
assays mixture contained (amongst other components described in materials and 
methods) membranes prepared from M. smegmatis, 100,000 cpm [14C]-R5P, 50 µg DP 
and 2 mM ATP. Individual assays were carried out at 37 °C and included the addition of 
no further additive, lane 1, M. smegmatis P60, lane 2, Mt-PrsA, lane 3, Mt-PrsA and 
NaWO4 and NaF both at a final concentration of 2 mM, lane 4, Mt-PrsA and M. 
smegmatis P60, lane 5, Mt-PrsA, M. smegmatis P60 and 2 mM of both NaWO4 and NaF, 
lane 6 and finally Mt-PrsA, M. smegmatis P60 and 2 mM ADP in lane 7. After an 
inubation at 37 °C for 30 min, assays were quenched and products extracted from the 
assay mix by organic solvent extraction as described in materials and methods. Samples 
relating to each assay were loaded onto a silica gel TLC plates, developed in 
CHCl3/CH3OH/CH3COONH4/NH4OH/H2O (180:140:9:9:23 v/v/v/v/v) and bands 
migrating to the position of DPA, DPR, DPX and DPPR were visualised by 
autoradiography, exposure of TLCs to X-ray film (Kodak X-Omat) and compared to 
previously isolated known standards (Mikusova et al., 2005; Alderwick et al., 2006a). 
 
Figure 4. Arabinofuranosyltransferase assays carried out via the Mt-PrsA-
dependent conversion of [14C]-R5P to p[14C]Rpp and subsequent chase into a neo-
glycolipid acceptor. The absolute dependence of the cell wall AraT enzymes on the 
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availability of pRpp was investigated using the neo-glycolipid acceptor α-D-Araf-(1→5)-
α-D-Araf-O-(CH2)7CH3 (Ara2). The basic assay contained (amongst other components 
described in materials and methods) 0.5 mg of membranes and P60 from M. smegmatis, 2 
mM α-D-Araf-(1→5)-α-D-Araf-O-(CH2)7CH3, 100,000 cpm [14C]-R5P, 50 µg DP and 2 
mM ATP. Assays were initiated by the addition of [14C]-R5P and incubated for 1 hour at 
37 °C. Individual assays carried out contained the addition of no Mt-PrsA, lane 1, 30 µg 
Mt-PrsA, lane 2, 30 µg Mt-PrsA and 100 µg/ml EMB, lane 3 and 30 µg Mt-PrsA and 2 
mM ADP in lane 4. [14C]-Araf-linked products were extracted from the assay mix as 
described in materials and methods and subsequently applied to a silica gel TLC plates, 
developed in CHCl3:CH2OH:H2O:NH4OH (65:25:3.6:0.5, v/v/v/v) and visualised by 
autoradiography from exposure of TLCs to X-ray film (Kodak X-Omat) (Lee et al., 1997; 
Seidel et al., 2007). 
 
Figure 5. Enzyme activity of Mt-PrsA and kinetic characterisation of R5P (A) and 
ATP (B) using a continuous enzyme coupled spectrophotometric assay. A, a plot of 
velocity (ν) of Mt-PrsA to increasing [R5P] in the presence of 50 mM Pi (?), 5 mM Pi 
(?) and no Pi (?). Data for 50 mM Pi fitted to equation 2 and data, obtained for 5 mM 
Pi and no Pi were fitted to equation 3. B, a plot of velocity (ν) of Mt-PrsA to increasing 
[ATP] in the presence of 50 mM Pi (?), 5 mM Pi (?) and no Pi (?), all of which were 
fitted to equation 4 using nonlinear regression analysis. All data points plotted (calculated 
mean) represent experiments performed in triplicate using three independent preparations 
of recombinant Mt-PrsA. Calculated standard errors (± Std. Errors) for kinetic constants 
are reported in the manuscript where appropriate. 
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Figure 6. Inhibition of Mt-PrsA activity by the addition of ADP when titrated with 
R5P (A) and ATP (B) using a continuous enzyme coupled spectrophotometric assay. 
A, a plot of velocity (ν) of Mt-PrsA response to increasing [R5P] in the presence of no 
ADP (?), 0.1 mM ADP (?) and 2 mM ADP (?). Data was fitted to equation 5 using 
nonlinear regression analysis. A, a plot of velocity (ν) of Mt-PrsA response to increasing 
[ATP] in the presence of no ADP (?), 0.1 mM ADP (?) and 2 mM ADP (?). Data was 
fitted to equation 6 using nonlinear regression analysis. All data points plotted (calculated 
mean) represent experiments performed in triplicate using three independent preparations 
of recombinant Mt-PrsA. Calculated standard errors (± Std. Errors) for kinetic constants 
are reported in the manuscript where appropriate. 
 
Figure 7. Mt-PrsA self-assembly analysis using analytical ultracentrifugation. 
Sedimentation velocity experiments were conducted to investigate the oligomeric state of 
Mt-PrsA in solution in the presence of no additional ligands (black line), 5 mM R5P (red 
line), 5 mM ATP (blue line) and 5 mM ADP (green line). Individual plots represent the 
molar mass dristribution c(M) vs the apparent molecular weight (Da). Arrows indicate the 
calculated oligomeric state of Mt-PrsA in each sedimentation velocity experiment. 
 
Figure 8. Binding kinetics of R5P (A) and the ATP analogue (AMPPNP) (B) to Mt-
PrsA using Intrinsic Tryptophan Fluorescence Spectroscopy. Intrinsic tryptophan 
fluorescence spectroscopy was used to determine the binding properties of Mt-PrsA for 
its substrates R5P and ATP. Ligand binding assays were carried out as described in 
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materials and methods. A, a plot of ∆Femission vs [R5P] in the presence of no AMPPNP 
(?) and 5 mM AMPPNP (?) which was fitted to equation 7. B, a plot of ∆Femission vs 
[AMPPNP] in the presence of no R5P (?) and 5 mM R5P (?) which was fitted to 
equation 9. 
 
Figure 9. Binding kinetics of ADP and the ATP to Mt-PrsA using Intrinsic 
Tryptophan Fluorescence Spectroscopy. Intrinsic tryptophan fluorescence 
spectroscopy was used to determine the binding properties of Mt-PrsA for it’s the 
allosteric inhibitor ADP and in competition with ATP. Ligand binding assays were 
carried out as described in materials and methods. A, a plot of ∆Femission vs [ADP] (?) 
which was fitted to equation 8. B, a plot of ∆Femission vs [ATP] in the presence of no ADP 
(?), 0.1 mM ADP (?) and 2.0 mM ADP (?) which was fitted to equation 10. 
 
Figure 10. Sequence alignment of various prokaryotic pRpp synthetases. Protein 
sequences from M. tuberculosis (Mt_PrsA), M. smegmatis (Ms_PrsA), M. leprae 
(Ml_PrsA), C. glutamicum (Cg_PrsA), S. coleicolor (Sc_Prs), B. subtilis (Bs_Prs), E. coli 
(Ec-Prs) and the three PrsA isoforms (Human_PrsA1-3) were aligned using CLUSTALW 
and annotated with ESPRIPT. Green triangles represent residues involved in catalysis. 
Blue circles indicate conserved and open blue circles highlight non-conserved residues 
involved in allosteric regulation. His109 and Gly111 are highlighted with red stars, 
indicating two residues only found in the flexible loop region of Corynebacterianeae 
PrsA homologues. The magenta diamonds indentify the location of the residues involved 
in the formation of a salt bridge in Bs-PrsA and Human-PrsA1. 
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Figure 11. Homology model of Mt-PrsA. A, Mt-PrsA arranged into its hexameric 
quaternary conformation. Carbon atoms of the ADP ligands located at the catalytic and 
regulatory sites of the Mt-PrsA hexamer are coloured in orange and green, respectively. 
Red spheres located at K10, D169, G194, D205-V208 and F322 indicate regions of the 
Mt-PrsA dimmer that include insertions or deletions with respect to the Bs-Prs structure. 
The triangle in the middle represents 3-fold symmetry, where as the arrow parallel to the 
plane indicates 2-fold rotational symmetry. Catalytic (B) and regulatory (C) sites of the 
Mt-PrsA homology model. The yellow and blue spheres indicate A85/G88 and 
S109/G111 substitution between the Bs-Prs and Mt-PrsA structures, respectively. 
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Fig. 6 
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Fig. 7 
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Fig. 8 
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Fig. 9 
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Fig. 10 
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